I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Matthew Jenusaitis net worth and biography

Matthew Jenusaitis Biography and Net Worth

Director of enVVeno Medical

Mr. Jenusaitis has over 30 years of health care experience with an emphasis on building and selling companies that develop medical devices to treat vascular diseases. He is currently the Chief of Staff and Chief of Innovation and Transformation for the UC San Diego Health System. Over the course of his career, Mr. Jenusaitis has been on the board of directors or a top executive at Pulsar Vascular which was sold to Johnson and Johnson, Creagh Medical, which was sold to SurModics, Precision Wire Components, which was sold to Creganna Medical, and ev3, which was sold to Covidian and later purchased by Medtronics. In addition, Mr. Jenusaitis was the President of the Peripheral Division at Boston Scientific and was an Executive in Residence at Warburg Pincus. Mr. Jenusaitis has an MBA from the University of California, Irvine, a Masters Degree in Biomedical Engineering from Arizona State University, and a Bachelors Degree in Chemical Engineering from Cornell University.

What is Matthew Jenusaitis' net worth?: The estimated net worth of Matthew Jenusaitis is at least $12,056.58 as of August 25th, 2021. Mr. Jenusaitis owns 4,842 shares of enVVeno Medical stock worth more than $12,057 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Jenusaitis may own. Learn More about Matthew Jenusaitis' net worth.
How do I contact Matthew Jenusaitis?: The corporate mailing address for Mr. Jenusaitis and other enVVeno Medical executives is 70 DOPPLER, IRVINE CA, 92618. enVVeno Medical can also be reached via phone at (949) 261-2900 and via email at [email protected]. Learn More on Matthew Jenusaitis' contact information.
Has Matthew Jenusaitis been buying or selling shares of enVVeno Medical?: Matthew Jenusaitis has not been actively trading shares of enVVeno Medical during the last quarter. Most recently, on Wednesday, August 25th, Matthew Jenusaitis bought 1,300 shares of enVVeno Medical stock. The stock was acquired at an average cost of $7.70 per share, with a total value of $10,010.00. Following the completion of the transaction, the director now directly owns 4,842 shares of the company's stock, valued at $37,283.40. Learn More on Matthew Jenusaitis' trading history.
Who are enVVeno Medical's active insiders?: enVVeno Medical's insider roster includes Robert Berman (CEO), Francis Duhay (Director), Marc Glickman (SVP), Robert Gray (Director), and Matthew Jenusaitis (Director). Learn More on enVVeno Medical's active insiders.
Are insiders buying or selling shares of enVVeno Medical?: In the last year, insiders at the sold shares 1 times. They sold a total of 8,334 shares worth more than $51,837.48. The most recent insider tranaction occured on March, 13th when CTO Hamed Alavi sold 8,334 shares worth more than $51,837.48. Insiders at enVVeno Medical own 16.0% of the company. Learn More about insider trades at enVVeno Medical.
Information on this page was last updated on 3/13/2024.

Matthew Jenusaitis Insider Trading History at enVVeno Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/25/2021	Buy	1,300	$7.70	$10,010.00	4,842

Matthew Jenusaitis Buying and Selling Activity at enVVeno Medical

enVVeno Medical Company Overview

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Today's Range

Now: $2.49

$2.45

$2.74

50 Day Range

MA: $3.22

$2.49

$3.65

2 Week Range

Now: $2.49

$2.45

$6.97

Volume

691,785 shs

Average Volume

112,245 shs

Market Capitalization

$43.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

I was wrong. Dead wrong.

From Porter & Company | Ad